Improving the outcome of adoptive cell transfer by targeting tumor escape

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Kaluza, Karen M ^a   Vile, Richard ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Adoptive T cell therapy; Cyclophosphamide; Immunostimulatory chemotherapy; Melanoma; Tumor escape

Indexed keywords

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL TRANSFER; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOSTIMULATION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY;

EID: 84886944594     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22059     Document Type: Article

References (10)

1. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116.
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/ NEJMoa1103849.
3. Till BG, Jensen MC, Wang JJ, Qian XJ, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119:3940-50; PMID:22308288; http://dx.doi.org/10.1182/blood-2011-10-387969.
4. Bernatchez C, Radvanyi LG, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 2012; 39:215-26; PMID:22484193; http://dx.doi.org/10.1053/j.seminoncol.2012.01.006.
5. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011; 29:550-7; PMID:21663987; http://dx.doi. org/10.1016/j.tibtech.2011.04.009.
6. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191.
7. Kaluza KM, Kottke T, Diaz RM, Rommelfanger D, Thompson J, Vile RG. Adoptive transfer of Cytotoxic T Lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther 2012; 23:1054-64; PMID:22734672; http://dx.doi. org/10.1089/hum.2012.030.
8. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen H-R, Goldberg MV, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009; 69:4309-18; PMID:19435909; http://dx.doi.org/10.1158/0008-5472.CAN-08-4102.
9. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621.
10. Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res 2012; 72:4753-64; PMID:22836753; http://dx.doi.org/10.1158/0008-5472.CAN-12-0600.